Innovent Biologics' (HKG:1801) new drug application for arcotatug tavatecan was accepted by China's National Medical Products Administration and granted priority review, according to a Thursday Hong Kong bourse filing.
The application was submitted after an international multi-center phase 3 clinical study of the drug reached the primary endpoint after completing the per-protocol first interim analysis.
The drug demonstrated excellent efficacy and a tolerable safety profile in the treatment of advanced gastric cancer.